A proactive medical necessity review program reduces revenue loss associated with outpatient medical benefit drugs.
Purpose A common denial trend that occurs with "outpatient medical benefit drugs" (ie, medications covered by a medical benefit plan and administered in an outpatient visit) is payers not requiring or permitting prior authorization (PA) proactively, yet denying the drug after administration for medi...
| Publicado en: | American Journal of Health-System Pharmacy Vol. 78; no. 17; pp. 1591 - 1600 |
|---|---|
| Autores principales: | , , , |
| Formato: | algorithm tables/charts Journal Article |
| Publicado: |
Oxford University Press / USA
Sep2021
|
| Acceso en línea: | Ver este registro en EBSCOhost |